Mollica V.; Di Nunno V.; Cimadamore A.; Lopez-Beltran A.; Cheng L.; Santoni M.; Scarpelli M.; Montironi R.; Massari F., Molecular mechanisms related to hormone inhibition resistance in prostate cancer, «CELLS», 2019, 8, Article number: 43 , pp. 1 - 15 [Scientific article]Open Access
Di Nunno V.; Santoni M.; Massari F., New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 471 - 471 [Scientific article]
Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F, New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes., «CLINICAL GENITOURINARY CANCER», 2019, 1, pp. E871 - E877 [Scientific article]
Di Nunno, Vincenzo; Mollica, Veronica; Santoni, Matteo; Gatto, Lidia; Schiavina, Riccardo; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes, «CLINICAL GENITOURINARY CANCER», 2019, 17, pp. 871 - 877 [Scientific article]
Di Nunno V.; Mollica V.; Massari F., N-Myc a key gene promoting a worst prostate cancer progression, «TRANSLATIONAL CANCER RESEARCH», 2019, 8, pp. 15 - 17 [Scientific article]
Mollica V.; Di Nunno V.; Gatto L.; Santoni M.; Cimadamore A.; Cheng L.; Lopez-Beltran A.; Montironi R.; Pisconti S.; Battelli N.; Massari F., Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution, «CLINICAL DRUG INVESTIGATION», 2019, 39, pp. 503 - 519 [Scientific article]
Santoni, Matteo; Maiorani, Giada; Faloppi, Luca; Di Nunno, Vincenzo; Gatto, Lidia; Massari, Francesco; Battelli, Nicola, Optimizing renal function and outcome of patients with cT2 renal cell carcinoma, «ANNALS OF TRANSLATIONAL MEDICINE», 2019, 7, Article number: S39 , pp. 1 - 3 [Scientific article]Open Access
Mollica V.; Di Nunno V.; Massari F., Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma, «CHINESE CLINICAL ONCOLOGY», 2019, 8, Article number: 20190405 , pp. 1 - 4 [Scientific article]
Nunno V.D.; Mollica V.; Gatto L.; Santoni M.; Cosmai L.; Porta C.; Massari F., Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis, «IMMUNOTHERAPY», 2019, 11, pp. 631 - 643 [Scientific article]
Saeed O.; Lopez-Beltran A.; Fisher K.W.; Scarpelli M.; Montironi R.; Cimadamore A.; Massari F.; Santoni M.; Cheng L., RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications, «JOURNAL OF CLINICAL PATHOLOGY», 2019, 72, pp. 135 - 139 [Scientific article]
Massari F.; Di Nunno V.; Santoni M., Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417–27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 340 - 341 [Scientific article]
Massari F.; Di Nunno V.; Santoni M.; Gatto L.; Mollica V.; Porta C., Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 603 - 604 [Scientific article]
Santoni M.; Montironi R.; Battelli N.; Massari F., Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842–3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma, «EUROPEAN UROLOGY», 2019, 75, pp. 64 - 66 [Scientific article]
Mollica V.; Di Nunno V.; Gatto L.; Santoni M.; Scarpelli M.; Cimadamore A.; Lopez-Beltran A.; Cheng L.; Battelli N.; Montironi R.; Massari F., Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor, «CANCERS», 2019, 11, Article number: 830 , pp. 1 - 16 [Scientific article]Open Access
Prisciandaro M.; Ratta R.; Massari F.; Fornarini G.; Caponnetto S.; Iacovelli R.; De Giorgi U.; Facchini G.; Scagliarini S.; Sabbatini R.; Caserta C.; Peverelli G.; Mennitto A.; Verzoni E.; Procopio G., Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program, «AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS», 2019, 42, pp. 42 - 45 [Scientific article]
